Core Insights - FMC Corporation has launched its fluindapyr technology with the approval of Tremisia fungicide in Ukraine, marking its first introduction in the EMEA region [1][9] - The approval allows FMC to access over 10 million hectares of Ukrainian farmland, enhancing disease management options for local growers [2][3][9] Product Launch and Market Impact - The Tremisia fungicide is designed to combat significant diseases such as Alternaria, Sclerotinia in sunflowers, and Septoria and rust in wheat [1][9] - Ukraine, being a major exporter of sunflower, oilseed rape, and wheat, is positioned to benefit from this advanced fungicide technology [2] Strategic Partnerships - FMC has partnered with Corteva to expand the use of fluindapyr in the U.S. corn and soybean markets, targeting tough foliar diseases [4] Financial Guidance - The company maintains its 2025 revenue guidance at $4.15-$4.35 billion, with adjusted EBITDA projected at $870-$950 million, reflecting a 1% increase at the midpoint [5] - Adjusted EPS remains unchanged at $3.26-$3.70, and free cash flow is expected to be between $200 million and $400 million [5] Stock Performance - FMC's stock has declined by 21.3% over the past year, contrasting with the industry's growth of 10.3% [6]
FMC's Tremisia Fungicide Debuts in EMEA Region After Approvals